EUVIMEDEUVIMED entdecken
Validierungsstudie

Evaluation of the Rheumatoid Arthritis Observation of Biologic Therapy risk score in Japanese patients with rheumatoid arthritis starting first biologic disease–modifying antirheumatic drugs: A validation study using the Institute of Rheumatology, Rheumatoid Arthritis cohort data

Tomoaki Higuchi, Eiichi Tanaka iD, Eisuke Inoue, Mai Abe, Kumiko Saka, Eri Sugano, Naohiro Sugitani, Yoko Higuchi, Moeko Ochiai, Rei Yamaguchi, Katsunori Ikari, Hisashi Yamanaka und 1 weitere

Modern Rheumatology · 2024

DOI: 10.1093/mr/road066 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Tomoaki Higuchi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This article aims to examine the ability of the Rheumatoid Arthritis Observation of Biologic Therapy (RABBIT) risk score to predict the occurrence of serious infections in Japanese patients with rheumatoid arthritis (RA), after initiating their first biologic disease–modifying antirheumatic drug (bDMARD).

Methods

We used data from the Institute of Rheumatology, Rheumatoid Arthritis cohort from 2008 to 2020. Patients with RA who were started on their first bDMARDs were included. Those with missing data required to calculate the score were excluded. A receiver operating characteristic curve was used to evaluate the discriminatory ability of the RABBIT score.

Results

A total of 1081 patients were enrolled. During the 1-year observational period, 23 (1.7%) patients had serious infections; the most frequent one was bacterial pneumonia (n = 11, 44%). The median RABBIT score in the serious infection group was significantly higher than that in the non-serious infection group [2.3 (1.5–5.4) vs 1.6 (1.2–2.5), P < .001]. The area under the receiver operating characteristic curve for the occurrence of serious infections was 0.67 (95% confidence interval 0.52–0.79), suggesting that the score had low accuracy.

Conclusions

Our present study revealed that the RABBIT risk score did not have sufficient discriminatory ability for predicting the development of severe infections in Japanese patients with RA after initiating their first bDMARD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsHumansFemaleMaleMiddle AgedJapanAgedRisk AssessmentBiological ProductsCohort StudiesAdultBiological TherapyEast Asian People

Stichwörter der Autor:innen

Antirheumatic agentsinfectionobservational studyrheumatoid arthritisvalidation study

Substanzen

Antirheumatic AgentsBiological Products

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
  • Division of Multidisciplinary Management of Rheumatic Diseases, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
  • Showa University Research Administration Centre, Showa University, Tokyo, Japan.
  • Department of Orthopaedic Surgery, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
  • Department of Rheumatology, Sanno Medical Centre, Tokyo, Japan.

ORCID-Profile: Eiichi Tanaka

Zitieren

APA

Higuchi, T., Tanaka, E., Inoue, E., Abe, M., Saka, K., Sugano, E., Sugitani, N., Higuchi, Y., Ochiai, M., Yamaguchi, R., Ikari, K., Yamanaka, H., & Harigai, M. (2024). Evaluation of the Rheumatoid Arthritis Observation of Biologic Therapy risk score in Japanese patients with rheumatoid arthritis starting first biologic disease–modifying antirheumatic drugs: A validation study using the Institute of Rheumatology, Rheumatoid Arthritis cohort data. Modern Rheumatology. https://doi.org/10.1093/mr/road066

Vancouver

Higuchi T, Tanaka E, Inoue E, Abe M, Saka K, Sugano E, et al. Evaluation of the Rheumatoid Arthritis Observation of Biologic Therapy risk score in Japanese patients with rheumatoid arthritis starting first biologic disease–modifying antirheumatic drugs: A validation study using the Institute of Rheumatology, Rheumatoid Arthritis cohort data. Modern Rheumatology. 2024. doi:10.1093/mr/road066

BibTeX
@article{Higuchi2024,
  author = {Higuchi, Tomoaki and Tanaka, Eiichi and Inoue, Eisuke and Abe, Mai and Saka, Kumiko and Sugano, Eri and Sugitani, Naohiro and Higuchi, Yoko and Ochiai, Moeko and Yamaguchi, Rei and Ikari, Katsunori and Yamanaka, Hisashi and Harigai, Masayoshi},
  title = {Evaluation of the Rheumatoid Arthritis Observation of Biologic Therapy risk score in Japanese patients with rheumatoid arthritis starting first biologic disease–modifying antirheumatic drugs: A validation study using the Institute of Rheumatology, Rheumatoid Arthritis cohort data},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/road066}
}
Kostenlos starten →